Recent findings

Normal BP in neonates depends on a variety of factors, including gestational age, postnatal age, and birth weight, and may be influenced by other antenatal

conditions. The incidence of neonatal hypertension is low, and it is most often seen in infants with concurrent conditions such as chronic lung disease (CLD) or renal Selleckchem AC220 disease, or in those that have undergone umbilical arterial catheterization. Although few data exist on efficacy and safety of antihypertensive medications in neonates, a wide variety of medications have been utilized in those who do require treatment. Hypertension resolves over time in most infants, although robust long-term outcome data are lacking.

Summary

Our understanding of neonatal hypertension continues to evolve. Although better data are available on normal BP and the incidence of hypertension, we still need studies focused on appropriate treatment and long-term prognosis.”
“Parkinson’s disease (PD) is a complex genetic disorder that is associated with environmental risk factors and aging. Vertebrate genetic models, especially mice, have

PND-1186 aided the study of autosomal-dominant and autosomal-recessive PD. Mice are capable of showing a broad range of phenotypes and, coupled with their conserved genetic and anatomical structures, provide unparalleled molecular and pathological tools to model human disease. These models used in combination with aging and PD-associated toxins have expanded our understanding of PD pathogenesis. Attempts to refine PD

animal models using conditional approaches have yielded in vivo nigrostriatal degeneration Acalabrutinib research buy that is instructive in ordering pathogenic signaling and in developing therapeutic strategies to cure or halt the disease. Here, we provide an overview of the generation and characterization of transgenic and knockout mice used to study PD followed by a review of the molecular insights that have been gleaned from current PD mouse models. Finally, potential approaches to refine and improve current models are discussed.”
“A total of 40 years have already passed since the pioneering work of McCord and Fridovich on erythrocuprein superoxide dismutase (SOD) activity. This modern scientific ‘Odyssey’ has been accompanied by a series of successes in the fields of biochemistry, biomedicine and proteomics. In this article, we resume the main strides in these fields, mainly aiming at delivering an exhaustive portrait of SOD’s involvement in several oxidative stress-triggered threats to human health, including neurodegenerative disorders (amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s diseases), cardiovascular diseases, cancer and aging.